Moffitt Cancer Center Cell Coast Conference 2024

Spotlight Breakthroughs in Cellular Immunotherapy: CAR-T, TIL & TCR Therapies for Hematologic and Solid Tumors

The Moffitt Cancer Center Cell Coast Conference 2024 is an innovative educational program dedicated to the rapidly expanding field of cellular immunotherapy. As the inaugural Cell Coast Conference, this event brings together leading experts in hematologic malignancies, solid tumors, cellular engineering, and immunotherapy to discuss the latest breakthroughs transforming cancer treatment.

Focused on translating scientific innovation into real-world clinical practice, the conference explores cutting-edge cellular therapies including CAR T-cell therapy, Tumor-Infiltrating Lymphocyte (TIL) therapy, T-cell Receptor (TCR) therapies, and bispecific antibodies. Participants gain practical insights into patient selection, toxicity management, operational readiness, manufacturing challenges, referral pathways, and the integration of cellular therapies into routine oncology care.

Unlike many immunotherapy meetings that focus primarily on hematologic malignancies, Cell Coast 2024 places strong emphasis on the expanding role of cellular therapies in solid tumors such as melanoma, lung cancer, and sarcoma, highlighting the next frontier of cancer immunotherapy.

Product Details

• Format: 15 Videos + 15 Audios + 15 Subtitle Files (.VTT) + 17 PDFs
• Total Size: 5.99 GB
• Course Date: October 2024
• Location: Moffitt Cancer Center, Tampa, Florida
• Access: On-Demand

Program Overview

This conference delivers advanced education on the science, clinical application, and operational implementation of modern cellular therapies.

Key areas of focus include:

• CAR T-cell therapy
• Tumor-Infiltrating Lymphocyte (TIL) therapy
• T-cell Receptor (TCR) therapies
• Bispecific antibodies
• Cellular immunotherapy
• Multiple myeloma
• Lymphoma
• Melanoma
• Lung cancer
• Sarcoma
• Cytokine Release Syndrome (CRS)
• Neurotoxicity (ICANS)
• Cellular therapy logistics
• Point-of-care manufacturing
• Community oncology integration

Participants gain valuable knowledge for implementing these transformative therapies across diverse oncology settings.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Evaluate real-world outcomes of CAR T-cell therapy in lymphoma and multiple myeloma.
• Compare clinical trial results with routine clinical practice experiences.
• Assess the emerging role of TIL therapy in melanoma and solid tumors.
• Analyze the clinical potential of TCR-based therapies for cancer treatment.
• Manage toxicities associated with cellular therapies and bispecific antibodies.
• Develop effective referral pathways between community and academic cancer centers.
• Understand operational requirements for cellular therapy programs.
• Evaluate innovative manufacturing approaches that improve access to advanced therapies.

Core Topics Covered

CAR T-Cell Therapy

The conference provides comprehensive updates on CAR-T therapy.

Topics include:

• Real-world treatment outcomes
• Lymphoma management
• Multiple myeloma applications
• Patient selection
• Long-term follow-up
• Clinical implementation

Experts discuss how outcomes compare with pivotal clinical trials.

Tumor-Infiltrating Lymphocyte (TIL) Therapy

Dedicated sessions explore:

• TIL therapy development
• Metastatic melanoma treatment
• Solid tumor applications
• Patient eligibility
• Treatment logistics
• Future clinical directions

Faculty review emerging evidence supporting TIL therapy beyond melanoma.

T-Cell Receptor (TCR) Therapies

Participants examine:

• Engineered T-cell therapies
• Solid tumor targets
• Synovial sarcoma treatment
• Afamitresgene autoleucel
• Clinical development pathways
• Future therapeutic opportunities

Experts discuss the expanding role of TCR technology in oncology.

Bispecific Antibodies

The conference reviews:

• Mechanisms of action
• Clinical applications
• Combination strategies
• Toxicity management
• Integration with cellular therapies

Participants gain practical guidance for incorporating these agents into treatment algorithms.

Cellular Therapy for Solid Tumors

A major emphasis of the meeting is extending immunotherapy beyond hematologic cancers.

Topics include:

• Melanoma
• Lung cancer
• Sarcoma
• Emerging targets
• Tumor microenvironment challenges
• Novel engineering approaches

Faculty discuss opportunities and barriers in solid tumor immunotherapy.

Cytokine Release Syndrome (CRS)

Important educational sessions focus on:

• Early recognition
• Severity grading
• Prevention strategies
• Evidence-based treatment
• Clinical monitoring

Participants learn best practices for managing one of the most significant cellular therapy toxicities.

Neurotoxicity (ICANS)

The conference addresses:

• Immune effector cell-associated neurotoxicity syndrome
• Neurologic monitoring
• Diagnostic approaches
• Treatment protocols
• Long-term outcomes

Experts provide practical recommendations for patient safety.

Community Oncology Integration

A unique aspect of the conference is its focus on collaborative care.

Topics include:

• Referral pathways
• Shared care models
• Long-term monitoring
• Communication strategies
• Expanding patient access

Faculty discuss how community oncologists and academic centers can work together effectively.

Operational Readiness & Program Development

Sessions explore real-world implementation challenges.

Topics include:

• Infrastructure requirements
• Staffing models
• Bed capacity planning
• Manufacturing delays
• Financial considerations
• Program growth strategies

Participants gain valuable operational insights for developing cellular therapy programs.

Point-of-Care Manufacturing

Emerging innovations include:

• Local CAR-T production
• Reduced manufacturing timelines
• Cost reduction strategies
• Enhanced patient access
• Future delivery models

Experts discuss how these advances may reshape cellular therapy delivery.

Educational Features

✔ CAR-T & Cellular Therapy Updates

✔ TIL & TCR Therapy Advances

✔ Solid Tumor Immunotherapy Focus

✔ Real-World Clinical Outcomes

✔ CRS & ICANS Management

✔ Community Oncology Integration

✔ Operational Readiness Strategies

✔ Emerging Manufacturing Innovations

Target Audience

This course is ideal for:

• Medical Oncologists
• Hematologists
• Cellular Therapy Specialists
• Bone Marrow Transplant Physicians
• Oncology Pharmacists
• Oncology Nurses
• Advanced Practice Providers
• Immunotherapy Teams
• Research Scientists
• Clinical Investigators
• Hematology-Oncology Fellows
• Academic Faculty

Why This Course Stands Out

✔ Strong focus on both hematologic and solid tumor immunotherapy

✔ Practical guidance for real-world implementation

✔ Covers CAR-T, TIL, TCR, and bispecific therapies

✔ Addresses operational and logistical challenges

✔ Includes cutting-edge manufacturing innovations

✔ Emphasizes collaboration between academic and community oncology

✔ Features expert leaders in cellular therapy

✔ Provides actionable strategies for modern cancer care

Clinical & Educational Value

The Moffitt Cancer Center Cell Coast Conference 2024 provides an advanced review of the rapidly evolving field of cellular immunotherapy. Through expert-led presentations and practical discussions, participants gain critical knowledge on CAR-T therapy, TIL therapy, TCR-based treatments, bispecific antibodies, toxicity management, and operational implementation strategies. The program equips oncology professionals with the tools needed to expand patient access and improve outcomes in both hematologic and solid tumor malignancies.

+ Topics:

• Updates on Approved CAR-T for Lymphoma
• CAR-T for ALL
• CAR-T Strategies for Multiple Myeloma
• Bi-specifics for Myeloma
• Cellular Therapies for Myeloid Malignancies
• Melanoma TILs
• Surgical Considerations for TIL Procurement
• Novel Cell Therapies for Thoracic Malignancies
• Afami-cel TCR for Sarcoma
• Intravesical TIL for Bladder Cancer
• Point of Care CAR T Manufacturing
• Real World CAR-T for Multiple Myeloma
• Infections Occurring in our ICE T Patient Population
• CAR-T in Autoimmune Diseases
• NK Cellular Therapies
• Business Operations of Cellular Therapies